Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HEC-151 Injection
HEC-151 · 1 trial · 1 indication
Frequency, type and severity of adverse events/serious adverse events.
Evaluation the heart rate of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.
Evaluation the PR interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.
Evaluation the QTcF interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.
Evaluation the QRS interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.
Evaluation the body temperature of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.
Evaluation the blood pressure of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.
Evaluation the pulse of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.
Evaluation the respiration of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.
| Arm | Type | Description |
|---|---|---|
| HEC-151 Injection | EXPERIMENTAL | The participants received an abdominal subcutaneous HEC-151 Injection in the morning of Day 1. |
| Insulin Degludec | ACTIVE_COMPARATOR | The participants received an abdominal subcutaneous injection of Insulin Degludec in the morning of Day 1. |
| Placebo | PLACEBO_COMPARATOR | The participants received an abdominal subcutaneous Injection of placebo in the morning of Day 1. |
| Name | Type | Description |
|---|---|---|
| HEC-151 Injection | DRUG | Subcutaneous injection in the abdominal area |
| Degludec insulin | DRUG | Subcutaneous injection in the abdominal area |
| Placebo | DRUG | Subcutaneous injection in the abdominal area |
Inclusion Criteria: 1. Voluntarily participate in the trial and sign the informed consent form, understanding and abiding by the research procedures; 2. When signing the informed consent form, men aged 18-45 years old (including the boundary value) are eligible; 3. During the screening process, mal...
HEC-151 is an investigational small molecule being developed by Sunshine Biopharma Inc. It is formulated as an injection and is currently in Phase 1 clinical development. The drug is being studied in healthy adult males, with its therapeutic area classified as other.
HEC-151 is being studied for use in healthy adult males as part of a Phase 1 clinical trial. The trial is a single-ascending dose study designed to evaluate the drug's effects in this population. The specific condition being investigated is healthy adult male volunteers.
HEC-151 is being developed by Sunshine Biopharma Inc., a company traded under the ticker SBFM. The drug is currently in Phase 1 clinical development, with an active trial recruiting participants in China.
HEC-151 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is a single-ascending dose study in healthy adult males, with 81 participants enrolled.
HEC-151 is being studied in a Phase 1 clinical trial with the identifier NCT07376200. The trial is titled "Single-ascending Dose Study of HEC-151 Injection" and is currently recruiting participants in China. It is a placebo-controlled, randomized study enrolling 81 healthy adult males aged 18 years and older.
Yes, HEC-151 is also known as HEC-151 Injection. The drug is administered as an injection and is being studied in a Phase 1 clinical trial under the name HEC-151 Injection. The trial is a single-ascending dose study in healthy adult males.